有机阴离子转运多肽1B1的遗传药理学进展

摘要/Abstract

摘要： 人体存在多种类型的药物转运体,对于药物的吸收、分布和排泄起重要作用。参与药物跨膜转运的转运体功能受影响,将可能导致诸多临床药物的疗效、毒副作用甚至药物相互作用的发生。在各种影响因素中,遗传多态性所起的作用最为重要,可导致基因表达和蛋白功能发生改变。目前,阐明转运体基因的多态性以及基因型与表型之间的相互关系已成为应用遗传信息指导临床个体化用药的必要步骤。本文就肝脏有机阴离子转运多肽1B1(OATP1B1[OATP-C],编码基因SLCO1B1)基因多态性对药代动力学和药效动力学的影响及其临床意义等方面的进展作一综述。

关键词: OATP1B1, 基因多态性, 转运, 药代动力学, 药效

Abstract: Many types of drug transporters are expressed in different organs.The transporters play important roles in drug absorption, distribution and excretion, and lead to consequences for interindividual differences in disposition kinetics, interaction profiles of clinical drugs, susceptibility to side effects and treatment efficacy.The genetic polymorphisms have been shown to alter both the expression and function of their gene products.The identification of allelic variations and their functional confirmations is a necessary step towards the use of genetic information for personalized medicine.This review focuses on the role of organic anion transporting polypeptide 1B1 (OATP1B1) gene polymorphisms in pharmacokinetic and pharmacodynamic consequences in pharmacotherapy.

Key words: OATP1B1, polymorphism, transport, pharmacokinetics, drug efficacy

中图分类号:

R969

张伟, 贺毅憬, 周宏灏. 有机阴离子转运多肽1B1的遗传药理学进展[J]. 中国临床药理学与治疗学, 2008, 13(7): 721-729.

ZHANG Wei, HE Yi-jing, ZHOU Hong-hao. Progress and research in pharmacogenetics of OATP1B1[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(7): 721-729.

参考文献

[1] Zär ZM, Eloranta JJ, Stieger B, et al. Pharmacogenetics of OATP (SLC21 SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney[J]. Pharmacogenomics, 2008, 9(5): 597-624.
[2] Tamai I, Nezu J, Uchino H, et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family[J]. Biochem Biophys Res Commun, 2000, 273(1): 251-260.
[3] Abe T, Kakyo M, Tokui T, et al. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1[J]. J Biol Chem, 1999, 274 (24): 17159-17163.
[4] Hsiang B, Zhu Y, Wang Z, et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters[J]. J Biol Chem, 1999, 274(52): 37161-37168.
[5] Nakai D, Nakagomi R, Furuta Y, et al. Human liverspecific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes[J]. J Pharmacol Exp Ther, 2001, 297(3): 861-867.
[6] Shitara Y, Itoh T, Sato H, et al. Inhibition of transportermediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporine A[J]. J Pharmacol Exp Ther, 2003, 304(2): 610-616.
[7] Bolego C, Poli A, Cignarella A, et al. Novel statins: pharmacological and clinical results[J]. Cardiovasc Drugs Ther, 2002, 16(3): 251-257.
[8] Niemi M. Role of OATP transporters in the disposition of drugs[J]. Pharmacogenomics, 2007, 8(7): 787-802.
[9] Xu LY, He YJ, Zhang W, et al. Organic anion transporting polypeptide-1B1 haplotypes in Chinese patients[J]. Acta Pharmacol Sin, 2007, 28(10): 1693-1697.
[10] Richard B. Kim, 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: what's it all about[J]. Clin Pharmacol Ther, 2004, 75(5): 381-385.
[11] PasanenMK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1[J]. Pharmacogenomics, 2008, 9(1): 19-33.
[12] Nozawa T, Nakajima M, Tamai I, et al. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis[J]. J Pharmacol Exp Ther, 2002, 302(2): 804-813.
[13] Tirona RG, Leake BF, Merino G, et al. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European-and African-Americans[J]. J Biol Chem, 2001, 276 (38): 35669-35675.
[14] Kameyama Y, Yamashita K, Kobayashi K, et al. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1 ＊5, SLCO1B1 ＊15 and SLCO1B1 ＊ 15 + C1007G, by using transient expression systems of HeLa and HEK293 cells[J]. Pharmacogenet Genomics, 2005, 15(7): 513-522.
[15] Nishizato Y, Ieiri I, Suzuki H, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics[J]. Clin Pharmacol Ther, 2003, 73(6): 554-565.
[16] Mwinyi J, Johne A, Bauer S, et al. Evidence for inverse effects of OATP-C (SLC21A6) ＊5 and ＊1b haplotypes on pravastatin kinetics[J]. Clin Pharmacol Ther, 2004, 75 (5): 415-421.
[17] Niemi M, Schaeffeler E, Lang T, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)[J]. Pharmacogenetics, 2004, 14(7): 429-440.
[18] Simonson SG, Raza A, Martin PD, et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine[J]. Clin Pharmacol Ther, 2004, 76(2): 167-177.
[19] Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment[J]. Clin Pharmacol Ther, 2005, 78(4): 330-341.
[20] Hirano M, Maeda K, Shitara Y, et al. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans[J]. J Pharmacol Exp Ther, 2004, 311(1): 139-146.
[21] Chung JY, Cho JY, Yu KS, et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers[J]. Clin Pharmacol Ther, 2005, 78(4): 342-350.
[22] Niemi M, Backman JT, Kajosaari LI, et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics[J]. Clin Pharmacol Ther, 2005, 77(6): 468-478.
[23] Zhang W, He YJ, Han CT, et al. Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide [J]. Br J Clin Pharmacol, 2006, 62(5): 567-572.
[24] Nozawa T, Minami H, Sugiura S, et al. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms[J]. Drug Metab Dispos, 2005, 33 (3): 434-439.
[25] Han JY, Lim HS, Shin ES, et al. Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer [J]. Lung Cancer, 2008, 59(1): 69-75.
[26] Takane H, Miyata M, Burioka N, et al. Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1 ＊15 allele[J]. Ther Drug Monit, 2007, 29(5): 666-668.
[27] Morimoto K, Oishi T, Ueda S, et al. A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy[J]. Drug Metab Pharmacokinet, 2004, 19(6): 453-455.
[28] Zineh I. Pharmacogenetics of response to statins[J]. Curr Atheroscler Rep, 2007, 9(3): 187-194.
[29] Cui Y, Konig J, Leier I, et al. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6[J]. J Biol Chem, 2001, 276(13): 9626-9630.
[30] Ieiri I, Suzuki H, Kimura M, et al. Influence of common variants in the pharmacokinetic genes (OATP1B1, UGT1A1, andMRP2) on serum bilirubin levels in healthy subjects[J]. Hepatol Res, 2004, 30(4): 91-95.
[31] Huang MJ, Kua KE, Teng HC, et al. Risk factors for severe hyperbilirubinemia in neonates[J]. Pediatr Res, 2004, 56(5): 682-689.
[32] Zhang W, Chen BL, Ozdemir V, et al. SLCO1B1 521T->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients[J]. Br J Clin Pharmacol, 2007, 64 (3): 346-352.
[33] Iimori RT, Tabara Y, Kusuhara H, et al. Effect of genetic polymorphism of OATP-C (SLCO1B1) on the lipid-lowering response to HMG-CoA reductase inhibitors[J]. Drug Metab Pharmacokin, 2004, 19(5): 375-380.
[34] Morimoto K, Ueda S, Seki N, et al. Candidate gene approach for the study of genetic factors involved in HMGCoA reductase inhibitor-induced rhabdomyolysis[R]. 18th JSSX annual meeting, Sapporo, Japan, 2003: 8PE-32.
[35] Niemi M, Kivisto KT, Hofmann U, et al. Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1) [J]. Br J Clin Pharmacol, 2005, 59(5): 602-604.
[36] Niemi M, Neuvonen PJ, Hofmann U, et al. Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype ＊ 17[J]. Pharmacogenet Genomics, 2005, 15(5): 303-309.